Galapagos increases share capital through warrant exercises
May 19 2016 - 4:25PM
Galapagos NV (Euronext & NASDAQ: GLPG)
announces a share capital increase arising from warrant
exercises. Galapagos issued 140,770 new ordinary shares on 19
May 2016, for a total capital increase (including issuance premium)
of €1,476,401.70.
CEO Onno van de Stolpe exercised 90,000 warrants
that were due to expire this month for a total of €895,500 and has
held the resulting shares. He consequently increased his holding to
a total of 628,289 Galapagos shares. In addition to Onno van de
Stolpe, one other Board member exercised 7,500 warrants. Moreover,
pursuant to the warrant exercise program of Galapagos' Executive
Committee, Executive Committee members automatically are committed
to exercise a minimum number of warrants, subject to certain
conditions. Pursuant to the rules of this program, two Executive
Committee members exercised an aggregate number of 5,000 warrants,
also to hold as shares.
In accordance with Belgian transparency
legislation[1], Galapagos notes that its total share capital
currently amounts to €249,394,222.78; the total number of
securities conferring voting rights is 46,109,508, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
2,981,227, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have
any convertible bonds or shares without voting rights
outstanding.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our maturing pipeline comprises Phase 2, Phase 1,
pre-clinical and discovery studies in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We
have discovered and developed filgotinib: in collaboration with
Gilead we aim to bring this JAK1-selective inhibitor for
inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel
medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiary Fidelta, has approximately 440
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& Corporate Communications +1 781 460 1784 |
Director
Communications +31 6 53 591 999 communications@glpg.com |
Paul van der Horst Director IR & Business Development +31 6 53
725 199 |
|
ir@glpg.com |
|
Forward-looking statements This release may contain
forward-looking statements, all of which involve certain risks and
uncertainties. These statements are often, but not always, made
through the use of words or phrases such as "anticipates,"
"believes," "continues," "could," "estimates," "expects,"
"intends," "may," "plans," "seeks," "stands to," "we believe,"
"will," "we intend," as well as similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition and liquidity, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent
with such forward-looking statements, they may not be predictive of
results or developments in future periods. Among the factors that
may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research
programs may not support registration or further development of its
product candidates due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities
and Exchange Commission (SEC) filings and reports, including in
Galapagos' most recent annual report on form 20-F filed with the
SEC and subsequent filings and reports filed by Galapagos with the
SEC. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or regulation.
[1] Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
GLPG increases share capital through warrant exercises
http://hugin.info/133350/R/2014102/746612.pdf
HUG#2014102
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024